QSAR studies on HIV-1 protease inhibitors using non-linearly transformed descriptors

Current Computer-Aided Drug Design

Volumn 8, Issue 1, 2012, Pages 10-49

  Saranya, Nallusamy ^a   Selvaraj, Samuel ^a  

^a BHARATHIDASAN UNIVERSITY   (India)

Author keywords

Binding affinity; Descriptors; Diverse inhibitors; HIV 1 protease; Non linear transformation; QSAR; Regression; TSAR

Indexed keywords

BINDING ENERGY; COMPUTATIONAL CHEMISTRY; COSMOLOGY; LINEAR REGRESSION; LINEAR TRANSFORMATIONS; MOLECULAR GRAPHICS; VIRUSES;

BINDING AFFINITIES; DESCRIPTORS; DIVERSE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS-1; HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE; NON-LINEAR TRANSFORMATIONS; QSAR; QSAR MODEL; REGRESSION; TSAR;

DISEASES;

(HYDROXYETHYLAMINO)SULFONAMIDE; (HYDROXYETHYLAMINO)SULFONAMIDE ISOSTERE; ACYCLIC COMPOUND; ARYLSULFONAMIDE; CYCLIC COMPOUND; DARUNAVIR; GW 0385; HEXAHYDROCYCLOPENTA[B]FURANYL URETHANE ANALOG 2; HEXAHYDROCYCLOPENTA[B]FURANYL URETHANE ANALOG 3; HEXAHYDROCYCLOPENTA[B]FURANYL URETHANE ANALOG 4; HUMAN IMMUNODEFICIENCY VIRUS 1 PROTEASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; METHYL 2 PYRROLIDINONE; N ALKOXYSULFONAMIDE ANALOG 19; N ALKOXYSULFONAMIDE ANALOG 20; OXAZOLIDINONE DERIVATIVE; TMC 126; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DATA BASE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84857725548     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/157340912799218534     Document Type: Article

References (43)

1. Kohl, N.E.; Emini, N.A.; Schleif, W.A.; Davis, L.J.; Heimbach, J.C.; Dixon, R.A.F.; Scolnick, E.M.; Sigal, I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA, 1988, 85, 4686-4690.
2. Peng, C.; Ho, B.K.; Chang, T.W.; Chang, N.T. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol., 1989, 63, 2550-2556.
3. Roberts, N.A.; Martin, J.A.; Kinchington, D.; Broadhurst, A.V.; Craig, J.C.; Duncan, I.B.; Galpin, S.A.; Handa, B.K.; Kay, J.; Krohn, A. Rational design of peptide-based HIV proteinase inhibitors. Science, 1990, 248, 358-361.
4. Dorsey, B.D.; Levin, R.B.; McDaniel, S.L.; Vacca, J.P.; Guare, J.P.; Darke, P.L.; Zugay, J.A.; Emini, E.A.; Schleif, W.A.; Quintero, J.C.; Lin, J.H.; Chen, I.-W.; Holloway, M.K.; Fitzgerald, P.M.D.; Axel, M.G.; Ostovic, D.; Anderson, P.S.; Huff, J.R. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem., 1994, 3, 3443-3451.
5. Kempf, D.J.; Marsh, K.C.; Denissen, J.F.; McDonald, E.; Vasavanonda, S.; Flentge, C.A.; Green, B.E.; Fino, L.; Park, C.H.; Kong, X.P.; Wideburg, N.E.; Saldivar, A.; Ruiz, L.; Kati, W.M.; Sham, H.L.; Robins, T.; Stewart, K.D.; Hsu, A.; Plattner, J.J.; Leonard, J.M.; Norbeck, D.W. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA, 1995, 92, 2484-2488.
6. Kaldor, S.W.; Kalish, V.J.; Davies, J.F.; Shetty, B.V.; Fritz, J.E.; Appelt, K.; Burgess, J.A.; Campanale, K.M.; Chirgadze, N.Y.; Clawson, D.K.; Dressman, B.A.; Hatch, S.D.; Khalil, D.A.; Kosa, M.B.; Lubbehusen, P.P.; Muesing, M.A.; Patick, A.K.; Reich, S.H.; Su, K.S.; Tatlock, J.H. Viracept (Nelfinavir Mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem., 1997, 40, 3979-3985.
7. Kim, E.E.; Baker, C.T.; Dwyer, M.D.; Murcko, M.A.; Rao, B.G.; Tung, R.D.; Navia, M.A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc., 1995, 117, 1181-1182.
8. Sham, H.L.; Kempf, D.J.; Molla, A.; Marsh, K.C.; Kumar, G.N.; Chen, C.M.; Kati, W.; Stewart, K.; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G.R.; Sun, E.; Japour, A.J.; Norbeck, D.W. ABT-378, a Highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother., 1998, 42, 3218-3224.
9. Robinson, B.S.; Riccardi, K.A.; Gong, Y.F.; Guo, Q.; Stock, D.A.; Blair, W.S.; Terry, B.J.; Deminie, C.A.; Djang, F.; Colonno, R.J.; Lin, P.F. MS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother., 2000, 44, 2093-2099.
10. Turner, S.R.; Strohbach, J.W.; Tommasi, R.A.; Aristoff, P.A.; Johnson, P.D.; Skulnick, H.I.; Dolak, L.A.; Seest, E.P.; Tomich, P.K.; Bohanon, M.J.; Horng, M.M.; Lynn, J.C.; Chong, K.T.; Hinshaw, R.R.; Watenpaugh, K.D.; Janakiraman, M.N.; Thaisrivongs, S. Tipranavir (PNU-140690): a potent, orally bioavailable non-peptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem., 1998, 41, 3467-3476.
11. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J.F.; Boross, P.; Wang, Y.-F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R.W.; Weber, I.T.; Ghosh, A.K.; Mitsuya, H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother., 2003, 47, 3123-3129.
12. Flexner, C. HIV drug development: the next 25 years. Nat. Rev. Drug Dis., 2007, 6, 959-966.
13. Sepkowitz, K.A. AIDS-the first 20 years. N. Engl. J. Med., 2001, 344, 1764-1772.
14. Garg, R. Gupta, S.P.; Gao, H.; Babu, M.S.; Debnath, A.K.; Hansch, C. Comparative quantitative structure-activity relationship studies on anti-HIV drugs. Chem. Rev., 1999, 99, 3525-3601.
15. Takkis, K.; Sulev, S. QSAR modeling of HIV-1 protease inhibition on six-and seven-membered cyclic urease. QSAR Comb. Sci., 2009, 28, 52-58.
16. Halder, A.K.; Jha, T. Validated predictive QSAR modeling of Naryl-oxazolidinone-5-carboxamides for anti-HIV protease activity. Bioorg. Med. Chem. Lett., 2010, 20, 6082-6087.
17. Basak, S.C.; Mills, D.; Garg, R.; Bhhatarai, B. A QSAR study of HIV protease inhibitors using theoretical decscriptors. Curr. Comput. Aided Drug Des., 2009, 6, 269-282.
18. Fernandez, M.; Caballero, J. Modeling of activity of cyclic urea HIV-1 protease inhibitors using regularized-artificial neural networks. Bioorg. Med. Chem., 2006, 14, 280-294.
19. Reddy, A.S.; Kumar, S.; Garg, R. Hybrid-genetic algorithm based descriptor optimization and QSAR models for predicting the biological activity of Tipranavir analogs for HIV protease inhibition. J. Mol. Graph Model., 2010, 28, 852-862.
20. Nair, C.; Jayatilleke, P.; Wang, X.; Miertus, S.; Welsh, W.J. Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor-and receptor-based properties. J. Med. Chem., 2002, 45, 973-983.
21. Nunthanavanit, P.; Anthony, N.G.; Johnston, B.F.; Mackay, S.P.; Ungwitayatorn, J. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of molecular field analysis. Arch. Pharm. Chem. Life Sci., 2008, 341, 357-364.
22. Durdagi, S.; Mavromoustakos, T.; Papadopoulos, M.G. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 6283-6289.
23. Lucić, B.; Nadramija, D.; Bašic, I.; Trinajstić, N. Toward generating simpler QSAR models: non-linear multivariate regression vs several neural network ensembles and some related methods. J. Chem. Inf. Comput. Sci., 2003, 43, 1094-1102.
24. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R.N.; Gilson, M.K. BindingDB: a web-accessible database of experimentally determined proteinligand binding affinities. Nucleic Acids Res., 2007, 35, D198-D201.
25. Baker, C.T.; Salituro, F.G.; Court, J.J; Deininger, D.D; Kim, E.E.; Li, B.; Novak, P.M.; Rao, B.G.; Pazhanisamy, S.; Schairer, W.C.; Tung, R.D. Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors. Bioorg. Med. Chem. Lett., 1998, 8, 3631-3636.
26. Salituro, F.G.; Baker, C.T.; Court, J.J.; Deininger, D.D; Kim, E.E.; Li, B.; Novak, P.M.; Rao, B.G.; Pazhanisamy, S.; Porter, M.D.; Schairer, W.C.; Tung, R.D. Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors. Bioorg. Med. Chem. Lett., 1998, 8, 3637-3642.
27. Miller, J.F.; Furfine, E.S.; Hanlon, M.H.; Hazen, R.J.; Ray, J.A.; Robinson, L.; Samano, V.; Spaltenstein, A. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. Bioorg. Med. Chem. Lett., 2004, 14, 959-963.
28. Ghosh, A.K.; Kulkarni, S.; Anderson, D.D.; Hong, L.; Baldridge, A.; Wang, Y.F.; Chumanevich, A.A.; Kovalevsky, A.Y.; Tojo, Y.; Amano, M.; Koh, Y.; Tang, J.; Weber, I.T.; Mitsuya, H. Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. J. Med. Chem., 2009, 52, 7689-7705.
29. Ghosh, A.K.; Leshchenko-Yashchuk, S.; Anderson, D.D.; Baldridge, A.; Noetzel, M.; Miller, H.B.; Tie, Y.; Wang, Y.F.; Koh, Y.; Weber, I.T.; Mitsuya, H. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. J. Med. Chem., 2009, 52, 3902-3914.
30. Ghosh, A.K.; Gemma, S.; Baldridge, A.; Wang, Y.F.; Kovalevsky, A.Y.; Koh, Y.; Weber, I.T.; Mitsuya, H. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. J. Med. Chem., 2008, 51, 6021-6033.
31. Ghosh, A.K.; Sridhar, P.R.; Leshchenko, S.; Hussain, A.K.; Li, J.; Kovalevsky, A.Y.; Walters, D.E.; Wedekind, J.E.; Grum-Tokars, V.; Das, D.; Koh, Y.; Maeda, K.; Gatanaga, H.; Weber, I.T.; Mitsuya, H. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J. Med. Chem., 2006, 49, 5252-5261.
32. Sherrill, R.G.; Furfine, E.S.; Hazen, R.J.; Miller, J.F.; Reynolds, D.J.; Sammond, D.M.; Spaltenstein, A.; Wheelan, P.; Wright, L.L. Synthesis and antiviral activities of novel N-alkoxyarylsulfonamide-based HIV protease inhibitors. Bioorg Med Chem Lett., 2005, 15, 3560-3564.
33. Ghosh, A.K.; Kincaid, J.F.; Cho, W.; Walters, D.E.; Krishnan, K.; Hussain, K.A.; Koo, Y.; Cho, H.; Rudall, C.; Holland, L.; Buthod, J. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg. Med. Chem. Lett., 1998, 8, 687-690.
34. TSAR Version 3.3. Accelrys Inc., San Diego, 2007.
35. Dessalew, N. QSAR study on piperidinecarboxamides as antiretroviral agents: An insight into the structural basis for HIV coreceptor antagonist activity. QSAR Comb. Sci., 2008, 27, 901-912.
36. Prabu, M.; Vijayan, R.S.K.; Ghoshal, N. Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FBQSSR, multi objective (MO-QSPR) and MIF studies. J. Comput. Aided Mol. Des., 2010, 24, 843-864.
37. 2. J. Mol. Graph. Model., 2002, 20, 269-276.
38. Saranya, N.; Selvaraj, S. Variation of protein binding cavity volume and ligand volume in protein-ligand complexes. Bioorg. Med. Chem. Lett., 2009, 19, 5769-5772.
39. Hall, L.H.; Kier, L.B. Reviews of Computational Chemistry. Boyd, D.; Lipkowitz, K.; Eds. VCH Publishers, Inc., 1991, Vol. 2, pp. 367-422.
40. Leach, A.R. An introduction to chemoinformatics, revised ed. Springer, 2007, pp. 57-59.
41. Natarajan, R.; Basak, S.C. Numerical characterization of molecular chirality of organic compounds. Curr. Comput. Aided Drug Des., 2009, 5, 13-22.
42. Gayathri, P.; Pande, V.; Sivakumar, R.; Gupta, S.P. A quantitative structure-activity relationship study on some HIV-1 protease inhibitors using molecular connectivity index. Bioorg. Med. Chem., 2001, 9, 3059-3063.
43. Eriksson, L.; Jaworska, J.; Worth, A.P.; Cronin, M.T.; McDowell, R.M.; Gramatica, P. Methods for reliability and uncertainty assessment and for applicability evaluations of classification-and regression-based QSARs. Environ. Health Perspect., 2003, 111, 1361-1375.